Online inquiry

IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ10067MR)

This product GTTS-WQ10067MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Melanoma research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001306129.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	2335
UniProt ID	P02751

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10067MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ3579MR	IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	BAY 1112623
GTTS-WQ3711MR	IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	BAY 94-9343
GTTS-WQ601MR	IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	6A3-IgG4
GTTS-WQ2745MR	IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	AMG-139
GTTS-WQ14609MR	IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	SC0001
GTTS-WQ11038MR	IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	MCLA-128
GTTS-WQ7186MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	FMC63 scFv-28Z CAR
GTTS-WQ15703MR	IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	VEGF Trap

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST